8-K: Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

Keros Therapeutics' Chair and CEO, Jasbir S. Seehra, will participate in a fireside chat at the Bank of America 2025 Global Healthcare Conference on May 13, 2025.

Summary

• Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its Chair and CEO, Jasbir S. Seehra, will participate in a fireside chat at the Bank of America 2025 Global Healthcare Conference.
• The conference presentation is scheduled for Tuesday, May 13, 2025, at 8:00 p.m. Eastern Time.
• A live audio webcast and an archived replay will be available in the Investors section of the Keros website for 90 days following the event.
• Keros is focused on developing therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-) family of proteins.
• The company's pipeline includes elritercept (KER-050) for cytopenias, cibotercept (KER-012) for pulmonary arterial hypertension and cardiovascular disorders, and KER-065 for neuromuscular diseases.

Sentiment

Score: 7

Explanation: The announcement is positive as it increases visibility for the company and its pipeline. It's a routine event, but beneficial for investor relations.

Positives

• Participation in the Bank of America Global Healthcare Conference provides Keros Therapeutics with an opportunity to increase visibility and communicate its progress to investors.
• The availability of a live webcast and archived replay enhances accessibility for interested parties.

Future Outlook

The company will continue to develop and commercialize novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGFfamily of proteins.

Management Comments

• Jasbir S. Seehra, Ph.D., Keros Chair and Chief Executive Officer, will participate in a fireside chat presentation at the Bank of America 2025 Global Healthcare Conference.

Industry Context

Keros Therapeutics' focus on TGFsignaling aligns with growing interest in targeted therapies for various diseases. Participation in the Bank of America Global Healthcare Conference is a common practice for biotech companies to engage with investors and showcase their pipelines.

Stakeholder Impact

• Shareholders may benefit from increased awareness of the company and its pipeline.
• Potential investors gain access to information about Keros Therapeutics' strategy and progress.

Next Steps

• Jasbir Seehra will participate in the fireside chat presentation at the Bank of America 2025 Global Healthcare Conference.
• Keros will provide a live audio webcast and archived replay of the presentation on its website.

Key Dates

Keywords

Keros Therapeutics, Healthcare Conference, TGF-beta, Elritercept, Cibotercept, KER-065, Biopharmaceutical, Clinical-stage